FTFinancial Times·1hBusiness
score-0.60
Biotech VC Business Model Shift Raises Questions About Long-Term Drug Development Costs
Original
Biotech VCs have become like bankers and we might all pay the price
“Headline uses alarming phrasing about paying a price and criticizes a systemic shift harming long-term drug development.”